Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769036 | 0.86 | ALDH1A1 (0.40) | ALDH1A1POLBMEN1KMT2ATDP1 | |
| SCHEMBL13706803 | 0.86 | ALDH1A1 (0.40) | ALDH1A1POLBMEN1KMT2ATDP1 | |
| SCHEMBL11036906 | 0.86 | ALDH1A1 (0.40) | ALDH1A1POLBMEN1KMT2ATDP1 | |
| SCHEMBL8504389 | 0.79 | POLB (0.31) | POLBMEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL14279226 | 0.78 | POLB (0.42) | ALDH1A1POLBMEN1KMT2ATDP1 | |
| SCHEMBL28965747 | 0.77 | MAPT (0.38) | ALDH1A1POLBMEN1KMT2ATDP1 | |
| SCHEMBL28965750 | 0.77 | MAPT (0.38) | ALDH1A1POLBMEN1KMT2ATDP1 | |
| SCHEMBL3410835 | 0.77 | CYP2C9 (0.53) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL3410836 | 0.77 | CYP2C9 (0.53) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL5352787 | 0.74 | ALDH1A1 (0.50) | ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673448-A1 | SUBSTITUTED NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4490161-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-119013279-A | Substituted tricyclic compounds as PARP inhibitors and uses thereof | 上海瑛派药业有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024179547-A1 | SUBSTITUTED NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC. (CN) | 2024-09-06 | — | — | WO | disclosed |
| WO-2023169226-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-09-14 | — | — | WO | disclosed |
| US-6914160-B1 | Oxytocin inhibitors | PFIZER INC (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1537085-A1 | OXYTOCIN INHIBITORS | Pfizer Limited (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020414-A1 | OXYTOCIN INHIBITORS | PFIZER LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | PARP1, PARP2, PARP3 | ALDH1A1 464/4885POLB 111/4885MEN1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.